Floatz logo

tng462

MTAP-deleted Solid Tumors

Servier Bio-Innovation LLCPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the MTAP-deleted Solid Tumors cohort.

Asset / SponsorPhaseRating
Bay 3713372
Bayer
Phase 1/2CC
s095035
Servier Bio-Innovation LLC
Phase 1/2CC
pep08
PharmaEngine
Phase 1CC

Same molecule, other indications

tng462 is also rated in:

pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
45 / 100
View asset →
RAS MutationDormant
CC
Indicative ·
45 / 100
View asset →
MTAP DeletionDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →